ObjectiveTo summarize the recent advances and clinical applications of molecular testing in thyroid cancer, discussing its significance in the era of precision medicine and future perspectives. MethodsA systematic review of relevant domestic and international literature was conducted to identify key molecular events closely associated with the development, progression, and prognosis of thyroid cancer, and to evaluate their clinical utility. ResultsMolecular testing provides critical auxiliary diagnostic information for thyroid nodules with indeterminate fine-needle aspiration results. Furthermore, for diagnosed differentiated thyroid cancer, molecular markers serve as important tools for precise risk stratification, guiding surgical extent, radioactive iodine therapy decisions, and targeted drug applications. ConclusionMolecular testing has become a cornerstone tool in advancing thyroid cancer management toward precision medicine, future efforts should focus on exploring novel molecular markers and optimizing clinical practice guidelines.
ObjectiveTo evaluate the effect of statins on amino-terminal brain natriuretic peptide (NT-proBNP), grade of New York Heart Association (NYHA), and ejection fraction (EF) in patients with chronic heart failure (CHF) using marginal structural model. MethodsA total of 297 patients with CHF from two medical centers in Shanxi province were sequentially enrolled from January 2018 to December 2020. The medical records were collected. Confounding factors were analyzed by t-test, Chi-square test and logistic regression. The random forest algorithm was used to estimate the weight of inverse probability. The marginal structural model was applied to evaluate the effects of statins. ResultsUsing logistic regression to exclude the influence of baseline confounders, the results showed that statins had no significant effect on the level of NT-proBNP in patients with CHF. The marginal structural model which excluded the influence of baseline confounders, time-dependent confounders and treatment conversion factors showed that statins significantly reduced NT-proBNP (OR=0.699, 95%CI 0.528 to 0.926, P=0.012). Statins had no significant effects on NYHA and EF. ConclusionStatins can effectively reduce the level of NT-proBNP in patients with CHF.